Welcome to AltruBio’s Exciting Announcement!

San Francisco, Jan. 19, 2023 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that David T. Rubin, M.D., Professor of Medicine at the University of Chicago and AltruBio Scientific, will be presenting a poster on AltruBio’s innovative immune checkpoint enhancer, ALTB-168, at the Crohn’s & Colitis Congress 2023. This is an exciting development in the field of immunological diseases and showcases AltruBio’s commitment to advancing medical research.

What is ALTB-168?

ALTB-168 is a novel immune checkpoint enhancer that has shown promising results in preclinical studies for the treatment of diseases such as Crohn’s and colitis. By modulating the immune system’s response, ALTB-168 has the potential to provide a new treatment option for patients with these debilitating conditions.

Impact on Individuals

For individuals suffering from Crohn’s and colitis, the development of ALTB-168 could mean a potential breakthrough in treatment options. This innovative therapy has the potential to improve quality of life and provide relief for those living with these chronic diseases.

Impact on the World

The presentation of ALTB-168 at the Crohn’s & Colitis Congress 2023 represents a significant advancement in the field of immunological research. The potential of this novel therapy to treat autoimmune diseases could have far-reaching implications for global health, offering new hope for patients worldwide.

In Conclusion

AltruBio’s announcement of the poster presentation on ALTB-168 at the Crohn’s & Colitis Congress 2023 is a testament to the company’s dedication to advancing medical research and developing innovative treatments for immunological diseases. The potential impact of ALTB-168 on individuals and the world is vast, promising new possibilities for the future of healthcare.